<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.biochemj.org">
<title>BJ Cell Immediate Publications</title>
<link>http://www.biochemj.org</link>
<description>Biochemical Journal RSS feed -- BJ Cell Immediate Publications</description>
<prism:issn>0264-6021</prism:issn>
<prism:eIssn>1470-8728</prism:eIssn>
<prism:publicationName>Biochemical Journal</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111912" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111627" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110348" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111839" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112061" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111236" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111861" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111837" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111351" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111996" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110554" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111589" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111255" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111889" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112078" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110868" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111994" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112044" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110687" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111360" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111661" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111678" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111831" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111653" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111398" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111220" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111363" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110605" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110247" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111461" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110535" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.biochemj.org/images/BJ_Name.gif" />
</channel>

<image rdf:about="http://www.biochemj.org/images/BJ_Name.gif">
<title>Biochemical Journal</title>
<url>http://www.biochemj.org/images/BJ_Name.gif</url>
<link>http://www.biochemj.org</link>
</image>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111912">
	<title><![CDATA[Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111912</link>
	<description><![CDATA[The nonsense mutations R518X-KCNQ1 and Q530X-KCNQ1 cause long-QT syndrome type 1 (LQT1) and result in a complete loss of <i>I</i><sub>Ks</sub> channel function. In this study we attempted to rescue the function of these mutants, in human embryonic kidney-293 cells, by promoting readthrough of their premature termination codons (PTCs) using the pharmacological agents G-418, gentamicin and PTC124. Gentamicin and G-418, acted to promote full-length channel protein expression from R518X at 100 &#x00B5;M and from Q530X at 1 mM. In contrast, PTC124 did not, at any dose tested, induce readthrough of either mutant. G-418 (1 mM) treatment also acted to significantly (<i>P</i>&lt;0.05) increase current density and peak-tail current density, at &#x002B;80 mV, for R518X, but not Q530X, to 58&#x00B1;11% and 82&#x00B1;17% of the wild-type level respectively. However, the biophysical properties of the currents produced, from R518X, while similar were not identical to wild-type as the voltage dependence of activation was significantly (<i>P</i>&lt;0.05) shifted by &#x002B;25 mV. Overall, these findings indicate that although functional rescue of LQT1 nonsense mutations is possible it is dependent on the degree of readthrough achieved and the effect on channel function of the amino acid substituted for the PTC. Such considerations will determine the success of future therapies.]]></description>
	<dc:creator>S C Harmer, J S Mohal, D Kemp, A Tinker</dc:creator>
	<dc:date>2012-02-06T15:18:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111912</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-02-06</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645">
	<title><![CDATA[The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645</link>
	<description><![CDATA[PCSK9 (proprotein convertase subtilisin/kexin type 9 ) plays an important role in control of plasma LDL cholesterol metabolism by modulating the degradation of hepatic LDL receptor. Previous studies demonstrated that PCSK9 is a target gene of the sterol regulatory element (SRE) binding protein 2 (SREBP2) that activates PCSK9 gene transcription through an SRE motif of the promoter. In addition to SREBP2, hepatic nuclear factor 1a (HNF1a) positively regulates PCSK9 gene transcription in hepatic cells through a binding site located 28 bp upstream from SRE. In this study, we have identified a novel histone nuclear factor P (HINFP) recognition motif residing between HNF1 motif and SRE that is essential for basal and sterol-regulated transcriptions of the PCSK9 promoter. Mutation of this motif lowers the basal promoter activity and abolishes the sterol-mediated repression as well as the SREBP2-induced activation of the PCSK9 promoter. We further show that the activity of SREBP2 in stimulating PCSK9 promoter activity is greatly enhanced by HINFP. Additional experiments suggest that HINFP and its cofactor NPAT form a functional complex, and NPAT may subsequently recruit HAT cofactor TRRAP to facilitate the histone H4 acetylation of the PCSK9 promoter. Knockdown of HINFP, NPAT or TRRAP each markedly reduces the amount of acetylated histone H4 on the PCSK9 promoter region and lowers PCSK9 protein levels. Importantly, by utilizing co-immunoprecipitation assays, we have demonstrated a direct interaction between SREBP2 and HINFP and its cofactor NPAT/TRRAP. These new findings, altogether, identify HINFP as a co-activator in SREBP-mediated transactivation of PCSK9 gene expression.]]></description>
	<dc:creator>H Li, J Liu</dc:creator>
	<dc:date>2012-01-31T12:11:41Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111645</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-31</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111627">
	<title><![CDATA[p53Ser15 Phosphorylation disrupts p53-RPA70 complex and induces RPA70-mediated DNA repair in hypoxia]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111627</link>
	<description><![CDATA[Cellular stressors are known to inhibit p53-RPA70 complex and RPA70 increases cellular DNA repair in cancer cells. We hypothesized that regulation of RPA70-mediated DNA repair might be responsible for inhibition of apoptosis in hypoxic tumors. We have shown that, in cancer cells, hypoxia disrupts p53-RPA70 complex thereby enhancing RPA70-mediated NER/NHEJ-repair. In normal cells, RPA70 binds to p53 N-terminus (NTD) whereas this binding is disrupted in hypoxia. Phosphorylation of p53-NTD is a crucial event in dissociating both NTD-RPA70 and p53-RPA70 complexes. Serial mutations at serine and threonine residues in NTD confirm that p53<sup>Ser15</sup>phosphorylation induces dissociation of p53-RPA70 complex in hypoxia. DNA-PK is shown to induce p53<sup>Ser15</sup>phosphorylation thus enhancing RPA70-mediated NER/NHEJ-repair. Further, RPA70 gene silencing induces significant increase in the cellular apoptosis in the resistant hypoxic cancer cells. We have thus elucidated a novel pathway showing how DNA-PK-mediated p53<sup>Ser15</sup> phosphorylation dissociates p53-RPA70 complex in enhancing NER/NHEJ-repair that causes resistance to apoptosis, in hypoxic cancer cells. This novel finding may open new strategies in developing cancer therapeutics based upon regulation of RPA70-mediated NER/NHEJ-repair.]]></description>
	<dc:creator>E Madan, R Gogna, U Pati</dc:creator>
	<dc:date>2012-01-30T13:47:24Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111627</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-30</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110348">
	<title><![CDATA[Fibulin-5 binds urokinase type plasminogen activator and mediates urokinase-stimulated {beta}1-integrin-dependent cell migration]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110348</link>
	<description><![CDATA[Urokinase-type plasminogen activator (uPA) stimulates cell migration through multiple pathways, including formation of plasmin and extracellular metalloproteinases, and binding to the uPA receptor (uPAR/CD87), integrins and lipoprotein receptor-related protein 1 (LRP1) that activate intracellular signaling pathways. We report uPA-mediated cell migration requires its interaction with fibulin-5. uPA stimulates migration of wild-type mouse embryonic fibroblasts (<i>FBLN5<sup>&#x002B;/&#x002B;</sup></i> MEFs), but has no effect on fibulin-5-deficient <i>FBLN5<sup>-/-</sup></i> MEFs. Migration of MEFs in response to uPA requires an interaction of fibulin-5 with integrins, as MEFs expressing a mutant fibulin-5 incapable of binding integrins (<i>FBLN5<sup>RGE/RGE</sup></i>MEFs) do not migrate in response to uPA. Moreover, a blocking anti-human &#x03B2;1 antibody inhibited the migration of pulmonary arterial smooth muscle cells (PASMCs) in response to uPA. Binding of uPA to fibulin-5 generates plasmin, which excises the integrin-binding N-terminal calcium-binding epidermal growth factor-like (cbEGF) domain, leading to loss of b1-integrin binding. We suggest that uPA promotes cell migration by binding to fibulin-5, initiating its cleavage by plasmin, which leads to its dissociation from b1 integrin and thereby unblocks integrin&#x2019;s capacity to facilitate cell motility.]]></description>
	<dc:creator>A Kapustin, V Stepanova, N Aniol, D B. Cines, A Poliakov, S Yarovoi, T Lebedeva, R Wait, G Ryzhakov, Y Parfyonova, Y Gursky, H Yanagisawa, M Minashkin, R Beabealashvilli, A Vorotnikov, A Bobik, V Tkachuk</dc:creator>
	<dc:date>2012-01-26T15:50:10Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110348</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-26</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111839">
	<title><![CDATA[ROCKII serine 1366 phosphorylation reflects the activation status]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111839</link>
	<description><![CDATA[Rho-associated protein kinase (ROCK), a downstream effector of RhoA, plays an important role in many cellular processes. Accumulating evidence has shown the involvement of ROCK activation in the pathogenesis of many diseases. However, a reagent capable of directly detecting ROCK activation is lacking. In this study, we show autophosphorylation of ROCKII in an <i>in vitro</i> kinase reaction. The phosphorylation sites were identified by mass spectrometry and the major phosphorylation site was found to be at the highly conserved S1366 residue. A phospho-specific antibody was generated that can specifically recognize ROCKII S1366 phosphorylation. We found that the extent of S1366 phosphorylation of endogenous ROCKII is correlated with that of myosin light chain phosphorylation in cells in response to RhoA stimulation, showing that S1366 phosphorylation reflects its kinase activity. In addition, ROCKII S1366 phosphorylation could be detected in human breast tumors by immunohistochemical staining. Our study provides a new approach for revealing ROCKII activation status by directly probing ROCKII S1366 phosphorylation in cells or tissues.]]></description>
	<dc:creator>H Chuang, C Yang, Y Tsay, C Hsu, L Tseng, Z Chang, H Lee</dc:creator>
	<dc:date>2012-01-24T14:38:48Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111839</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-24</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112061">
	<title><![CDATA[A NOVEL LECTIN FROM AGROCYBE AEGERITA SHOWS HIGH BINDING SELECTIVITY FOR TERMINAL N-ACETYLGLUCOSAMINE]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112061</link>
	<description><![CDATA[A novel lectin was isolated from the mushroom <i>Agrocybe aegerita</i> (designated AAL-2) by affinity chromatography with <i>N</i>-acetylglucosamine (GlcNAc) coupled Sepharose 6B after (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>precipitation. The AAL-2 coding sequence (1224 bp) was identified by performing a homologous search of the five tryptic peptides identified by mass spectrometry against the translated transcriptome of <i>A. aegerita</i>. The molecular weight of AAL-2 was calculated to be 43.175 kDa from mass spectrometry (MS), which was consistent with the data calculated from the amino acid sequence. To analyze the sugar binding properties of AAL-2, a glycan array composed of 465 glycan candidates was employed and the result showed that AAL-2 bound with high selectivity to terminal, nonreducing GlcNAc residues, and further analysis revealed that AAL-2 bound to terminal, nonreducing GlcNAc residues with higher affinity than previously well-known GlcNAc-binding lectins such as wheat germ agglutinin (WGA) and <i>Griffonia simplicifolia</i> lectin-II (GSL-II). Isothermal titration calorimetry (ITC) further showed that GlcNAc bound to AAL-2 in a sequential manner with moderate affinity. In the current study, we also evaluated the antitumor activity of AAL-2. The results showed that AAL-2 could bind to the surface of hepatoma cells, leading to induced cell apoptosis <i>in vitro</i>. Furthermore, AAL-2 exerted an anti-hepatoma effect via inhibition of tumor growth and prolongation of survival time of tumor bearing mice <i>in vivo</i>.]]></description>
	<dc:creator>S Jiang, Y Chen, M Wang, Y Yin, Y Pan, B Gu, G Yu, Y Li, B Wong, Y Liang, h sun</dc:creator>
	<dc:date>2012-01-23T15:09:25Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112061</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-23</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111236">
	<title><![CDATA[The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111236</link>
	<description><![CDATA[The non-steroidal anti-inflammatory drug (NSAID) indomethacin, a cyclooxygenase-1 and -2 inhibitor with anti-inflammatory and analgesic properties, is known to possess anticancer activity against colorectal cancer (CRC) and other malignancies in humans; however, the mechanism underlying the anticancer action remains elusive. Herein we show that indomethacin selectively activates the double-stranded RNA (dsRNA)-dependent protein kinase PKR in a cyclooxygenase-independent manner, causing rapid phosphorylation of the alpha-subunit of eukaryotic translation initiation-factor 2 (eIF2alpha) and inhibiting protein synthesis in colorectal carcinoma and other types of cancer cells. The PKR-mediated translational block was followed by inhibition of CRC cell proliferation and apoptosis induction. Indomethacin did not affect the activity of eIF2alpha-kinases PERK, GCN2 and HRI, and induced eIF2alpha phosphorylation in PERK-knockout and GCN2-knockout cells, but not in PKR-knockout cells or in human PKR-silenced CRC cells, identifying PKR as a selective target for indomethacin-induced translational inhibition. The fact that indomethacin induced PKR activity <i>in-vitro</i>, an effect reversed by PKR-inhibitor 2-aminopurine, suggests a direct effect of the drug in the kinase activation. The results identify PKR as a novel target of indomethacin, opening new scenarios on the molecular mechanisms underlying the pleiotropic activity of this traditional NSAID.]]></description>
	<dc:creator>C Brunelli, C Amici, M Angelini, C Fracassi, G Belardo, M Santoro</dc:creator>
	<dc:date>2012-01-23T14:57:01Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111236</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-23</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111861">
	<title><![CDATA[Transforming Growth Factor Beta-1 represses proximal tubular cell microRNA-192 expression via decreased Hepatocyte Nuclear Factor DNA binding]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111861</link>
	<description><![CDATA[MicroRNA-192 (miR-192) plays key roles in renal pathological and physiological responses, by repressing targets including Zeb1, Zeb2, and Wnk1. Here, we have studied regulation of miR-192 expression. We found that Transforming Growth Factor Beta-1 (TGF-b1) down-regulates miR-192 and miR-194, co-transcribed in the shared precursor pri-miR-192/194. Luciferase reporter analysis showed constitutive promoter activity within nucleotides &#x002B;21 to -223. We identified Hepatocyte Nuclear Factor and p53 binding sites within this region that were required for constitutive promoter activity, which was decreased by TGF-b1 via an Alk5-dependent mechanism. TGF-b1-treatment decreased HNF binding to the miR-194-2/192 promoter, while knockdown of HNF-1 inhibited mature miR-192 and -194 expression. miR-192, -194 and HNF expression were restricted to a defined subset of human tissues including kidney, small intestine, colon, and liver. Our data identify coordinated regulation of miR-192 and -194, with binding of HNF and p53 transcription factors necessary for activation of transcription, and TGF-b1 mediated repression <i>via</i> decreased HNF binding to its cognate promoter element.]]></description>
	<dc:creator>R H. Jenkins, J Martin, A O. Phillips, T Bowen, D J. Fraser</dc:creator>
	<dc:date>2012-01-23T12:05:33Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111861</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-23</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111837">
	<title><![CDATA[Green tea polyphenol EGCG induces lipid raft clustering and apoptotic cell death by activating protein kinase C{delta} and acid sphingomyelinase through 67-kDa laminin receptor in multiple myeloma cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111837</link>
	<description><![CDATA[(&#xFF0D;)-Epigallocatechin-3-<i>O</i>-gallate (EGCG), the major polyphenol of green tea, has cancer chemopreventive and chemotherapeutic activities. EGCG selectively inhibits cell growth and induces apoptosis in cancer cells without adversely affecting normal cells; however, the underlying molecular mechanism <i>in vivo</i> is unclear. In this study, we show that EGCG-induced apoptotic activity is attributed to a lipid raft clustering mediated through 67-kDa laminin receptor (67LR) that is significantly elevated in multiple myeloma (MM) cells relative to normal peripheral blood mononuclear cells, and that acid sphingomyelinase (aSMase) is critical for the lipid raft clustering and the apoptotic cell death induced by EGCG. We also found that EGCG induces aSMase translocation to the plasma membrane and protein kinase C delta (PKC&#x03B4;) phosphorylation at Ser<sup>664</sup>, which was necessary for aSMase/ceramide signaling, via 67LR. Additionally, orally administered EGCG activated PKC&#x03B4; and aSMase in a murine MM xenograft model. These results elucidate a novel cell death pathway triggered by EGCG for the specific killing of MM cells.]]></description>
	<dc:creator>S Tsukamoto, K Hirotsu, M Kumazoe, Y Goto, K Sugihara, T Suda, Y Tsurudome, T Suzuki, S Yamashita, Y Kim, Y Huang, K Yamada, H Tachibana</dc:creator>
	<dc:date>2012-01-19T11:59:48Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111837</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-19</prism:publicationDate>
	<prism:section>BJ ChemBio</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111351">
	<title><![CDATA[{gamma}-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of PI 3-K/Akt and MAPK/ERK signaling pathways]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111351</link>
	<description><![CDATA[&#x03B3;-Enolase, a glycolytic enzyme, is expressed specifically in neurons. It exerts neurotrophic activity and has been suggested to regulate growth, differentiation, survival and regeneration of neurons. In this study, we investigated the involvement of &#x03B3;-enolase in PI 3-K/Akt (phosphatidylinositol 3-kinase/Akt) and MAPK/ERK (mitogen-activated protein kinase/ extracellular-signal-regulated kinase) signaling, the two pathways triggered predominantly by neurotrophic factors. While the PI 3-K/Akt pathway, rather than the MAPK/ERK pathway, is involved in &#x03B3;-enolase-enhanced cell survival, &#x03B3;-enolase-stimulated neurite outgrowth requires both pathways, i.e. the activation of both PI 3-K and ERK1/2, leading to subsequent expression of growth cone-specific GAP-43 protein. MEK (mitogen-activated protein kinase kinase) and PI 3-K inhibition blocked or attenuated the neurite outgrowth associated with dynamic remodeling of the actin-based cytoskeleton. We show that &#x03B3;-enolase&#x2013;mediated PI 3-K activation regulates RhoA kinase, a key regulator of actin cytoskeleton organization. Moreover, the inhibition of RhoA down-stream effector ROCK (Rho-associated kinase) results in enhanced &#x03B3;-enolase induced neurite outgrowth, accompanied by actin polymerization and its redistribution to growth cones. Our results show that &#x03B3;-enolase controls neuronal survival, differentiation and neurite regeneration, by activating PI 3-k/Akt and MAPK/ERK signaling pathways, resulting in down-stream regulation of the molecular and cellular processes of cytoskeleton reorganization and cell remodeling, activation of transcriptional factors and regulation of the cell cycle.]]></description>
	<dc:creator>A Hafner, N Obermajer, J Kos</dc:creator>
	<dc:date>2012-01-19T11:42:24Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111351</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-19</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111996">
	<title><![CDATA[Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111996</link>
	<description><![CDATA[Fibrosis is the formation of excess and abnormal fibrous connective tissue as a result of either a reparative or reactive process. A defining feature of connective tissue is its extracellular matrix, which provides structural support and also influences cellular activity. Two common human conditions that result from fibrosis are uterine fibroids (leiomyomas) and keloid scars. Because these conditions share a number of similarities and because their growth is due primarily to excessive extracellular matrix deposition, we compared the proteoglycans of uterine fibroids and keloid scars to corresponding normal tissues. Our analysis indicates that uterine fibroids and keloid scars contain higher amounts of proteoglycans relative to normal myometrium and normal adult skin, respectively. Proteoglycan composition is also different in the fibrotic tissues. Compared to unaffected tissues, uterine fibroids and keloid scars contain higher relative amounts of versican and lower relative amounts of decorin. There is also evidence for a higher level of versican catabolism in the fibrotic tissues compared to unaffected tissues. These qualitative and quantitative proteoglycan differences may play a role in the expansion of these fibrotic conditions and in their excessive matrix deposition and matrix disorganization due to effects on cell proliferation, TGF-&#x03B2; signaling, and/or collagen fibril formation.]]></description>
	<dc:creator>D A. Carrino, S Mesiano, N M. Barker, W W. Hurd, A I. Caplan</dc:creator>
	<dc:date>2012-01-19T11:22:29Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111996</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-19</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110554">
	<title><![CDATA[The Golgi-Associated Long Coiled-Coil Protein NECC1 Participates in the Control of the Regulated Secretory Pathway in PC12 Cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110554</link>
	<description><![CDATA[Golgi-associated long coiled-coil proteins, often referred to as <i>golgins</i>, are involved in the maintenance of the structural organization of the Golgi apparatus and the regulation of membrane traffic events occurring in this organelle. Little information is available on the contribution of golgins to Golgi function in cells specialized in secretion such as endocrine cells or neurons. Here, we characterize the intracellular distribution as well as the biochemical and functional properties of a novel long coiled-coil protein present in neuroendocrine tissues, <i>neuroendocrine long coiled-coil protein 1</i> (NECC1). Our studies show that NECC1 is a peripheral membrane protein displaying high stability to detergent extraction, which distributes across the Golgi apparatus in neuroendocrine cells. In addition, NECC1 partially localizes to post-Golgi carriers containing secretory cargo in PC12 cells. Overexpression of NECC1 resulted in the formation of juxtanuclear aggregates together with a slight fragmentation of the Golgi and a decrease in K<sup>&#x002B;</sup>-stimulated hormone release. In contrast, NECC1 silencing did not alter Golgi architecture but enhanced K<sup>&#x002B;</sup>-stimulated hormone secretion in PC12 cells. In all, our results identify NECC1 as a novel component of the Golgi matrix and support a role for this protein as a negative modulator of the regulated trafficking of secretory cargo in neuroendocrine cells.]]></description>
	<dc:creator>D Cruz-Garcia, A Diaz-Ruiz, Y Rabanal-Ruiz, J R. Peinado, F Gracia-Navarro, J P. Casta&#x00F1;o, M Montero-Hadjadje, M Tonon, H Vaudry, Y Anouar, R Vazquez-Martinez, M M Malagon</dc:creator>
	<dc:date>2012-01-18T12:34:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110554</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-18</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111589">
	<title><![CDATA[n-3 polyunsaturated fatty acids suppress phosphatidylinositol-(4,5)-bisphosphate dependent actin remodeling during CD4{+} T cell activation]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111589</link>
	<description><![CDATA[n-3 polyunsaturated fatty acids (PUFA), i.e. docosahexaenoic acid (DHA), found in fish oil, exhibit anti-inflammatory properties; however, the molecular mechanisms remain unclear. Since phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P<sub>2</sub>) resides in raft domains and DHA can alter the size of rafts, we hypothesized that PI(4,5)P<sub>2</sub> and downstream actin remodeling are perturbed by the incorporation of n-3 PUFA into membranes, resulting in suppressed T cell activation. CD4<sup>&#x002B;</sup> T cells isolated from <i>Fat-1</i> transgenic mice (membranes enriched in n-3 PUFA) exhibited a 50% decrease in PI(4,5)P<sub>2</sub>. Upon activation by plate bound anti-CD3/anti-CD28 or PMA/ionomycin, <i>Fat-1</i> CD4<sup>&#x002B;</sup> T cells failed to metabolize PI(4,5)P<sub>2</sub>. Furthermore, actin remodeling, failed to initiate in <i>Fat-1</i> CD4<sup>&#x002B;</sup> T cells upon stimulation; however, the defect was reversed by incubation with exogenous PI(4,5)P<sub>2</sub>. When <i>Fat-1</i> CD4<sup>&#x002B;</sup> T cells were stimulated with anti-CD3/anti-CD28 coated beads, the Wiskott-Aldrich syndrome protein (WASP) failed to translocate to the immunological synapse. The suppressive phenotype, consisting of defects in PI(4,5)P<sub>2</sub> metabolism and actin remodeling, were recapitulated in CD4<sup>&#x002B;</sup> T cells isolated from mice fed a 4% DHA triglyceride-enriched diet. Collectively, these data demonstrate that DHA alters PI(4,5)P<sub>2</sub> in CD4<sup>&#x002B;</sup> T cells, thereby suppressing the recruitment of WASP to the IS, and impairing actin remodeling in CD4<sup>&#x002B;</sup> T cells.]]></description>
	<dc:creator>T Y Hou, J M Monk, Y Fan, R Barhoumi, Y Q Chen, G M Rivera, D N McMurray, R S Chapkin</dc:creator>
	<dc:date>2012-01-18T11:24:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111589</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-18</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111255">
	<title><![CDATA[CNGA3 is expressed in inner ear hair cells and binds to an intracellular carboxy terminus domain of EMILIN1]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111255</link>
	<description><![CDATA[The molecular characteristics of cyclic nucleotide-gated (CNG) channels in auditory/vestibular hair cells are largely unknown, unlike those of CNG channels mediating sensory transduction in vision and olfaction. Here, we report full-length sequence for three CNGA3 variants in a hair cell preparation from the trout saccule with high identity to CNGA3 in olfactory receptor neurons/cone photoreceptors. A custom antibody targeting amino terminus sequence immunolocalized CNGA3 to the stereocilia and subcuticular plate region of saccular hair cells. The cytoplasmic carboxyl terminus of CNGA3 was found by yeast two-hybrid analysis to bind the carboxy terminus of elastin microfibril interface-located protein 1 (EMILIN1) in both the vestibular hair cell model and rat organ of Corti (OC). Specific binding between CNGA3 and EMILIN1 was confirmed with surface plasmon resonance analysis, predicting dependence on Ca<sup>2&#x002B;</sup> with a <i>K</i><sub>d</sub> = 1.6 x 10<sup>-6</sup> M for trout hair cell proteins and a <i>K</i><sub>d</sub> <i>= </i>2.7 x 10<sup>-7</sup> M for OC proteins at 68 &#x00B5;M Ca<sup>2&#x002B;</sup>. Pull-down assays indicated that the binding to OC CNGA3 was attributable to EMILIN1 intracellular sequence that follows a predicted transmembrane domain in the carboxy terminus. Saccular hair cells also express transcript for phosphodiesterase 6C (PDE6C), which in cone photoreceptors regulates degradation of cGMP used to gate CNGA3 in phototransduction. Taken together, the evidence supports the existence in saccular hair cells of a molecular pathway linking CNGA3, its binding partner EMILIN1 (and beta1-integrin) and cGMP-specific PDE6C, which is potentially replicated in cochlear outer hair cells, given stereociliary immunolocalizations of CNGA3, EMILIN1 and PDE6C.]]></description>
	<dc:creator>D Selvakumar, M J Drescher, J R Dowdall, K M Khan, J S Hatfield, N A Ramakrishnan, D G Drescher</dc:creator>
	<dc:date>2012-01-17T12:23:32Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111255</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-17</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111889">
	<title><![CDATA[Lipocalin-type Prostaglandin D Synthase Protects Against Oxidative Stress-induced Neuronal Cell Death]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111889</link>
	<description><![CDATA[Lipocalin-type prostaglandin D synthase (L-PGDS) is a dual functional protein, acting as a PGD<sub>2</sub>-producing enzyme and a lipid-transporter. L-PGDS is a member of the lipocalin superfamily and can bind a wide variety of lipophilic molecules. Here we show the protective effect of L-PGDS on H<sub>2</sub>O<sub>2</sub>-induced apoptosis in neuroblastoma cell line SH-SY5Y. L-PGDS expression was increased in H<sub>2</sub>O<sub>2</sub>-treated neuronal cells, and the L-PGDS level was highly associated with H<sub>2</sub>O<sub>2</sub>-induced apoptosis, indicating that L-PGDS protected the neuronal cells against H<sub>2</sub>O<sub>2</sub>-mediated cell death. Cell viability assay revealed that L-PGDS protected against H<sub>2</sub>O<sub>2</sub>-induced cell death in a concentration-dependent manner. Further, the titration of free-thiols in H<sub>2</sub>O<sub>2</sub>-treated L-PGDS revealed that H<sub>2</sub>O<sub>2</sub> reacted with the thiol of Cys65 of L-PGDS. The MALDI-TOF MS spectrum of H<sub>2</sub>O<sub>2</sub>-treated L-PGDS showed a 32-Da increase in the mass relative to that of the untreated protein, showing that the thiol was oxidized to sulfinic acid. The binding affinities of oxidized L-PGDS for lipophilic molecules were comparable to those of untreated L-PGDS. Taken together, these results demonstrate that L-PGDS protected against neuronal cell death by scavenging reactive oxygen species without losing its ligand-binding function. The novel function of L-PGDS could be useful for the suppression of oxidative stress-mediated neurodegenerative diseases.]]></description>
	<dc:creator>A Fukuhara, M Yamada, K Fujimori, Y Miyamoto, T Kusumoto, H Nakajima, T Inui</dc:creator>
	<dc:date>2012-01-16T14:00:57Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111889</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-16</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112078">
	<title><![CDATA[The Guanine-Nucleotide Exchange Factor (GEF) P-Rex1 is Activated by Protein Phosphatase 1{alpha} (PP1{alpha})]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112078</link>
	<description><![CDATA[P&#x2011;Rex1 is a guanine-nucleotide exchange factor (GEF) for the small G protein Rac that is activated by PIP<sub>3</sub> and Gbg subunits and inhibited by PKA. Here, we show that Protein Phosphatase 1a (PP1a) binds P&#x2011;Rex1 through an RVxF-type docking motif. PP1a activates P&#x2011;Rex1 directly <i>in vitro</i>, both independently of and additively to PIP<sub>3</sub> and Gbg. PP1a also substantially activates P&#x2011;Rex1 <i>in vivo</i>, both in basal and PDGF- or LPA-stimulated cells. The phosphatase activity of PP1a is required for P&#x2011;Rex1 activation. PP1b, a close homologue of PP1a, is also able to activate P&#x2011;Rex1, but less effectively. PP1a stimulates P-Rex1-mediated, Rac-dependent changes in endothelial cell morphology. Mass spectrometric analysis of wild-type P&#x2011;Rex1 and a PP1a-binding deficient mutant revealed that endogenous PP1a dephosphorylates P&#x2011;Rex1 on at least three residues, S834, S1001 and S1165. Site-directed mutagenesis of S1165 to alanine caused activation of P-Rex1 to a similar degree as did PP1a, confirming S1165 as a dephosphorylation site important in regulating P&#x2011;Rex1 Rac-GEF activity. In summary, we have identified a novel mechanism for direct activation of P&#x2011;Rex1 through PP1a-dependent dephosphorylation.]]></description>
	<dc:creator>M A Barber, A Hendrickx, M Beullens, H Ceulemans, D Oxley, S Thelen, M Thelen, M Bollen, H C E Welch</dc:creator>
	<dc:date>2012-01-16T12:34:24Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112078</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-16</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057">
	<title><![CDATA[3{'}-5{'}phosphoadenosine phosphate is an inhibitor of Poly(ADP-ribose) Polymerase 1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111057</link>
	<description><![CDATA[3&#x2019;-5&#x2019;phosphoadenosine phosphate (pAp) is a by-product of sulfur and lipid metabolism and has been shown to have strong inhibitory properties on RNA catabolism. We report here a new target of pAp, Poly(ADP-ribose) Polymerase 1 (PARP-1), a key enzyme in the detection of DNA single strand breaks. We show that pAp can interact with PARP-1 and inhibit its poly(ADP-ribosyl)ation activity. <i>In vitro</i>, inhibition of PARP-1 was detectable at micromolar concentrations of pAp and altered both PARP-1 automodification and heteromodification of histones. Analysis of the kinetic parameters revealed that pAp acted as a mixed inhibitor that modulates both the K<sub>M</sub> and the V<sub>M</sub> of PARP-1. In addition, we showed that upon treatment by lithium, a very potent inhibitor of the enzyme responsible of pAp recycling, HeLa cells exhibited a reduced level of poly(ADP-ribosyl)ation in response to oxidative stress. From these results, we propose that pAp might be a physiological regulator of PARP-1 activity.]]></description>
	<dc:creator>E Toledano, V Ogryzko, A Danchin, D Ladant, U Mechold</dc:creator>
	<dc:date>2012-01-12T14:34:48Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111057</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-12</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110868">
	<title><![CDATA[Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidines of HCV glycoprotein E1 and E2.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110868</link>
	<description><![CDATA[The protonation of histidine in acidic environments underpins its role in regulating the function of pH-sensitive proteins. For pH-sensitive viral fusion proteins, His protonation in the endosome leads to the activation of their membrane fusion function. The hepatitis C virus (HCV) glycoprotein E1/E2 heterodimer mediates membrane fusion within the endosome but the roles of conserved histidines in the formation of a functional heterodimer and in sensing pH changes is unknown. We examined the functional roles of conserved histidines located within E1 and E2. The E1 mutations, H222A/R, H298R, and H352A, disrupted E1-E2 heterodimerization and reduced virus entry. Five of 6 histidines located within the E2 receptor-binding domain (RBD) were important for the E2 fold, their substitution with Arg or Ala causing aberrant heterodimerization and/or CD81 binding. Distinct roles in E1/E2 heterodimerization and in virus entry were identified for His-691 and His-693, respectively, within the membrane-proximal stem region. Viral entry and cell-cell fusion at neutral and low pH were enhanced with H445R, indicating that the protonation state of His-445 is a key regulator of HCV fusion. However, H445R did not overcome the block to virus entry induced by bafilomycin A1 indicating a requirement for an endosomal activation trigger in addition to acidic pH.]]></description>
	<dc:creator>I Boo, K teWierek, F Douam, D LAVILLETTE, P Poumbourios, H Edelgard Drummer</dc:creator>
	<dc:date>2012-01-12T14:09:38Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110868</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-12</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111994">
	<title><![CDATA[Caveolae Optimize Tissue Factor-Factor VIIa Inhibitory Activity of Cell Surface Associated Tissue Factor Pathway Inhibitor]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111994</link>
	<description><![CDATA[Tissue factor pathway inhibitor (TFPI) is an anticoagulant protein that prevents intravascular coagulation through inhibition of factor Xa (fXa) and the tissue factor (TF)-factor VIIa complex (TF-fVIIa). Localization of TFPI within caveolae enhances its anticoagulant activity. To further define how caveolae contribute to TFPI anticoagulant activity, CHO cells were co-transfected with TF and membrane associated TFPI targeted to either caveolae (TFPI-GPI) or to bulk plasma membrane (TFPI-TM). Stable clones had equal expression of surface TF and TFPI. TX-114 cellular lysis confirmed localization of TFPI-GPI to detergent insoluble membrane fractions, while TFPI-TM localized to the aqueous phase. TFPI-GPI and TFPI-TM were equally effective direct inhibitors of fXa in amidolytic assays. However, TFPI-GPI was a significantly better inhibitor of TF-FVIIa than TFPI-TM, as measured in both amidolytic and plasma clotting assays. Disrupting caveolae by removing membrane cholesterol from EA.hy926 cells, which make TFPIa, CHO cells transfected with TFPIb, and HUVECs, did not affect their fXa inhibition but significantly decreased their inhibition of TF-fVIIa. These studies confirm and quantify the enhanced anticoagulant activity of TFPI localized within caveolae, demonstrate that caveolae enhance the inhibitory activity of both TFPI isoforms, and define the effect of caveolae as specifically enhancing the anti-TF activity of TFPI.]]></description>
	<dc:creator>S A. Maroney, P E. Ellery, J P. Wood, J P. Ferrel, C E. Bonesho, A E. Mast</dc:creator>
	<dc:date>2012-01-12T13:53:45Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111994</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-12</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112044">
	<title><![CDATA[The importance of an asymmetric distribution of acidic lipids for Synaptotagmin 1 function as a Ca2+ sensor]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20112044</link>
	<description><![CDATA[Synaptotagmin 1 (Syt1) is a major Ca<sup>2+</sup> sensor for synaptic vesicle fusion. Although Syt1 is known to bind to SNARE complexes and to the membrane, the mechanism by which Syt1 regulates vesicle fusion is controversial. Here we used <i>in</i> <i>vitro</i> lipid mixing assays to investigate the Ca<sup>2+</sup>-dependent Syt1 function in proteoliposome fusion. To study the role of acidic lipids, the concentration of negatively charged DOPS in the vesicle was varied. Syt1 stimulated lipid mixing by factors of 3-10 without Ca<sup>2+</sup>. However, with Ca<sup>2+</sup> there was additional factors of 2-5 enhancement. But the Ca<sup>2+</sup>-dependent stimulation was observed only when there was excess PS on the t-SNARE side, and if there was equal or more PS on v-SNARE side, the Ca<sup>2+</sup>-dependent stimulation was not observed. We found that Ca<sup>2+</sup> in a few ten &#x00B5;M level was sufficient to give rise to the maximal enhancement. The single vesicle fusion assay indicates that the Ca<sup>2+</sup>-dependent enhancement was mainly on docking while its effect on lipid mixing was small. Thus, for Syt1 to function as a Ca<sup>2+</sup> sensor, a charge asymmetry appears to be important and it may play a role in steering Syt1 to make productive <i>trans</i> binding to the plasma membrane.]]></description>
	<dc:creator>Y Lai, Y Shin</dc:creator>
	<dc:date>2012-01-09T15:31:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20112044</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-09</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420">
	<title><![CDATA[The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111420</link>
	<description><![CDATA[The essential cofactors coenzyme A (CoA), FAD and NAD<sup>+</sup> are synthesized outside the peroxisomes and therefore must be transported into the peroxisomal matrix where they are required for important processes. In this work we have functionally identified and characterized SLC25A17, which is the only member of the mitochondrial carrier family that has previously been shown to be localized in the peroxisomal membrane. Herein, recombinant and purified SLC25A17 was reconstituted into liposomes. Its transport properties and kinetic parameters demonstrate that SLC25A17 is a transporter of CoA, FAD, FMN, AMP and to a lesser extent of NAD<sup>+</sup>, adenosine 3&#x2019;,5&#x2019;-diphosphate (PAP) and ADP. SLC25A17 functioned almost exclusively by a counter-exchange mechanism, was saturable and inhibited by pyridoxal-5&#x2019;-phosphate and other mitochondrial carrier inhibitors. It was expressed to various degrees in all the human tissues examined. Its main function is probably to transport free CoA, FAD and NAD<sup>+</sup> into peroxisomes in exchange for intraperoxisomally generated PAP, FMN and AMP. This is the first report describing the identification and characterization of a transporter for multiple free cofactors in peroxisomes.]]></description>
	<dc:creator>G Agrimi, A Russo, P Scarcia, F Palmieri</dc:creator>
	<dc:date>2011-12-21T12:59:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111420</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-21</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110687">
	<title><![CDATA[The yeast vacuolar Rab GTPase Ypt7p has an activity beyond membrane recruitment of the HOPS/Class C Vps complex]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110687</link>
	<description><![CDATA[A previous report described lipid mixing of reconstituted proteoliposomes made using lipid mixtures that mimic the composition of yeast vacuoles. This lipid mixing required SNARE proteins, Sec18p and Sec17p (yeast NSF[1] and a-SNAP), and the HOPS/Class C Vps complex, but not the vacuolar Rab GTPase Ypt7p. The present study investigates the activity of Ypt7p in proteoliposome lipid mixing. Ypt7p is required for lipid mixing of proteoliposomes lacking cardiolipin. Omission of other lipids with negatively charged and/or small headgroups does not cause Ypt7p dependence for lipid mixing. Yeast vacuoles made from strains disrupted for cardiolipin synthase (CRD1) fuse to the same extent as vacuoles from strains with functional CRD1. Disruption of CRD1 does not alter dependence on Rab GTPases for vacuole fusion. It has been proposed that HOPS complex recruitment to membranes is the main function of Ypt7p. However, Ypt7p is still required for lipid mixing even when the concentration of HOPS complex in lipid-mixing reactions is adjusted such that cardiolipin-free proteoliposomes with or without Ypt7p bind equal amounts of HOPS. Ypt7p therefore must stimulate membrane fusion by a mechanism in addition to HOPS-membrane recruitment. This is the first demonstration of such a stimulatory activity &#x2013; that is, beyond bulk effector recruitment &#x2013; for a Rab GTPase.]]></description>
	<dc:creator>C Stroupe</dc:creator>
	<dc:date>2011-12-16T11:28:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110687</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-16</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111360">
	<title><![CDATA[A Molten Globule-to-Ordered Structure Transition of Drosophila melanogaster Crammer Is Required for its Ability to Inhibit Cathepsin]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111360</link>
	<description><![CDATA[<i>Drosophila melanogaster</i> crammer is a novel cathepsin inhibitor that is involved in long-term memory (LTM) formation. The mechanism by which the inhibitory activity is regulated remains unclear. Here we have shown that the oligomeric state of crammer is pH dependent. At neutral pH, crammer is predominantly dimeric <i>in vitro</i> as a result of disulfide bond formation, and is monomeric at acidic pH. Our inhibition assay shows that monomeric crammer, not disulfide bonded dimer, is a strong competitive inhibitor of cathepsin L. Crammer is a monomeric molten globule in acidic solution, a condition that is similar to the environment in the lysosome where crammer is likely located. Upon binding to cathepsin L, however, crammer undergoes a molten globule-to-ordered structural transition. Using high-resolution NMR spectroscopy, we have shown that a cysteine-to-serine point mutation at position 72 (C72S) renders crammer monomeric at pH 6.0 and that the structure of the C72S variant highly resembles that of wild-type crammer in complex with cathepsin L at pH 4.0. We have determined the first solution structure of propeptide-like protease inhibitor in its active form and examined in detail using a variety of spectroscopic methods the folding properties of crammer in order to delineate its biomolecular recognition of cathepsin.]]></description>
	<dc:creator>T Tseng, C Cheng, D Chen, M Shih, Y Liu, S Danny Hsu, P Lyu</dc:creator>
	<dc:date>2011-12-09T14:32:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111360</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-09</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111661">
	<title><![CDATA[Macromolecular and small molecule modulation of intracellular A{beta}42 aggregation and associated toxicity]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111661</link>
	<description><![CDATA[A&#x03B2; peptide has a central role in Alzheimer&#x2019;s disease (AD) where neuronal toxicity is linked to its extracellular and intracellular accumulation as oligomeric species. Searching for molecules that attenuate A&#x03B2; aggregation could uncover novel therapies for AD, but most studies in mammalian cells have inferred aggregation indirectly by assessing levels of secreted A&#x03B2; peptide. Here we establish a mammalian cell system for the direct visualisation of &#x03B2;-amyloid formation by expression of an A&#x03B2;<sub>42</sub>-EGFP fusion protein in the HEK cell line, T-REx293, and use this to identify both macromolecules and small molecules that reduced aggregation and associated cell toxicity. Thus, a molecular shield protein, AavLEA1, which limits aggregation of proteins with expanded polyglutamine (polyQ) repeats, is also effective against A&#x03B2;<sub>42</sub>-EGFP when co-expressed in T-REx293 cells. A screen of polysaccharide and small organic molecules from medicinal plants and fungi reveals one candidate in each category, PS5 and ganoderic acid DM, respectively, with activity against A&#x03B2; peptide. Both PS5 and ganoderic acid DM probably promote A&#x03B2; aggregate clearance indirectly through the proteasome. The model is therefore of value to study the effects of intracellular A&#x03B2; peptide on cell physiology, and to identify reagents that counteract those effects.]]></description>
	<dc:creator>S Chakrabortee, Y Liu, L Zhang, H R Matthews, H Zhang, N Pan, C Cheng, S Guan, D Guo, Z Huang, Y Zheng, A Tunnacliffe</dc:creator>
	<dc:date>2011-12-09T14:08:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111661</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-09</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111678">
	<title><![CDATA[Reprogramming of pancreatic exocrine cells towards a beta cell character using Pdx1, Ngn3 and MafA]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111678</link>
	<description><![CDATA[<i>Pdx1</i>, <i>Ngn3</i> and <i>MafA</i> have been reported to bring about the transdifferentiation of pancreatic exocrine cells to beta cells in vivo (Zhou et al. (2008) <i>Nature</i> 455, 627-630), We have investigated the mechanism of this process using a standard in vitro model of pancreatic exocrine cells, the rat AR42j-B13 cell line. We constructed a new adenoviral vector encoding all three genes, called <i>Ad-PNM</i>. When introduced into AR42j-B13 cells, <i>Ad-PNM</i> causes a rapid change to a flattened morphology, and a cessation of cell division. The expression of exocrine markers is suppressed. Both <i>insulin</i> genes are upregulated as well as a number of transcription factors normally characteristic of beta cells. At the chromatin level, histone tail modifications of the <i>Pdx1</i>, <i>Ins1</i> and <i>Ins2</i> gene promoters are shifted in a direction associated with gene activity, and the level of DNA CpG methylation is reduced at the <i>Ins1</i> promoter. The transformed cells secrete insulin and are capable of relieving diabetes in streptozotocin-treated NOD-SCID mice. However the transformation is not complete. The cells lack expression of several genes important for beta cell function and they do not show glucose-sensitive insulin secretion. We conclude that, for this exocrine cell model, although the transformation is dramatic, the reprogramming is not complete and lacks critical aspects of the beta cell phenotype.]]></description>
	<dc:creator>E Akinci, A Banga, L V Greder, J R Dutton, J M.W. Slack</dc:creator>
	<dc:date>2011-12-09T12:11:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111678</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-09</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111831">
	<title><![CDATA[Folded Functional Lipid-Poor Apolipoprotein A-I Obtained by Heating of High-Density Lipoproteins: Relevance to HDL Biogenesis]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111831</link>
	<description><![CDATA[High-density lipoproteins (HDL) remove cell cholesterol and protect from atherosclerosis. The major HDL protein is apolipoprotein A-I (apoA-I). Most plasma apoA-I circulates in lipoproteins, yet ~5% forms monomeric lipid-poor/free species. This metabolically active species is a primary cholesterol acceptor and is central to HDL biogenesis. Structural properties of lipid-poor apoA-I are unclear due to difficulties in isolating this transient species. We used thermal denaturation of human HDL to produce lipid-poor apoA-I. Analysis of the isolated lipid-poor fraction showed protein:lipid weight ratio 3:1, with apoA-I, phosphatidylcholine and cholesterol ester at approximate molar ratios of 1:8:1. Compared to lipid-free apoA-I, lipid-poor apoA-I showed slightly altered secondary structure and aromatic packing, reduced thermodynamic stability, lower self-associating propensity, increased adsorption to phospholipid surface, and comparable ability to remodel phospholipids and form reconstituted HDL. Lipid-poor apoA-I can be formed by heating of either plasma or reconstituted HDL. We propose the first structural model of lipid-poor apoA-I which corroborates its distinct biophysical properties and postulates the lipid-induced ordering of the labile C-terminal region. In summary, HDL heating produces folded functional monomolecular lipid-poor apoA-I that is distinct from lipid-free apoA-I. Increased adsorption to phospholipid surface and reduced C-terminal disorder may help direct lipid-poor apoA-I towards HDL biogenesis.]]></description>
	<dc:creator>S Jayaraman, G Cavigiolio, O Gursky</dc:creator>
	<dc:date>2011-12-08T11:26:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111831</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-08</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745">
	<title><![CDATA[A Cohesin-RAD21 Interactome]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745</link>
	<description><![CDATA[The cohesin complex holds the sister chromatids together from S phase until the metaphase-to-anaphase transition and ensures both their proper cohesin and timely separation. In addition to its canonical function in chromosomal segregation, cohesion has been suggested by several lines of investigation in recent years to play additional roles in apoptosis, DNA damage response, transcriptional regulation, and hematopoiesis. To better understand the basis of the disparate cellular functions of cohesin in these various processes, we have characterized a comprehensive protein interactome of cohesin-RAD21 by using three independent approaches: yeast 2-hybrid (Y2H) screening, immunoprecipitation-coupled-mass spectrometry (IP-M) of cytoplasmic and nuclear extracts from MOLT-4 T lymphocytes in the presence and absence of etoposide induced apoptosis, and affinity-pull down assays of chromatographically purified nuclear extracts from proapoptotic MOLT-4 cells. Our analyses revealed 112 novel protein interactors of cohesin RAD21 that function in different cellular processes including mitosis, regulation of apoptosis, chromosome dynamics, replication, transcription regulation, RNA processing, DNA damage response, protein modification and degradation, and cytoskeleton and cell motility. Identification of cohesin interactors provides a framework for explaining the various non-canonical functions of the cohesin complex.]]></description>
	<dc:creator>A K Panigrahi, N Zhang, S K Otta, D Pati</dc:creator>
	<dc:date>2011-12-07T12:10:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111745</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-07</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111653">
	<title><![CDATA[Targeting of proapoptotic TLR adaptor, SARM, to mitochondria: definition of critical region and residues in the signal sequence]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111653</link>
	<description><![CDATA[The fifth and the most well conserved member of the TLR adaptor, SARM, has been reported to be an important mediator of apoptosis. However, the exact cellular localization of SARM with respect to its role is unclear. Here we show that SARM specifically co-localizes with the mitochondria. Endogenous SARM is mainly found in the mitochondria. We demonstrated that the N terminal 27 amino acids (S27) of SARM, which is hydrophobic and polybasic, acts as a mitochondria-targeting signal sequence, associating SARM to the mitochondria. The S27 peptide has an inherent ability to bind to lipids and mitochondria. This sequence effectively translocates the soluble EGFP reporter into the mitochondria. Positioning S27 downstream of the EGFP abrogates its mitochondria-targeting ability. Transmission electron microscopy confirms the ability of S27 to import EGFP into the mitochondria. Importantly, by mutagenesis study, we delineated the specificity of the mitochondria-targeting ability to the Arginine residue at the 14<sup>th</sup> position. Arg14Ala SARM mutant also showed reduced apoptotic potential when compared to the wild type. Taken together S27, which is a <i>bona fide</i> signal sequence that targets SARM to the mitochondria, explains the proapoptotic activity of SARM.]]></description>
	<dc:creator>P Panneerselvam, L Pradeepkumar Singh, B Ho, J Chen, J L Ding</dc:creator>
	<dc:date>2011-12-07T11:51:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111653</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-07</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111398">
	<title><![CDATA[Angiotensin II-dependent Phosphorylation at Ser-11/Ser-18 and Ser-938 shift the E2 Conformations of Rat Kidney Na,K-ATPase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111398</link>
	<description><![CDATA[Kidney plasma membranes, which contain a single a-1 isoform of Na,K-ATPase, simultaneously contain two sub-conformations of EP<sub>2</sub>, differing in their rate of digoxin release in response to Na and ATP. Treating cells with angiotensin II (Ang II) somehow changes the conformation of both, because it differentially inhibits the rate of digoxin release. We test if Ang II regulates release by increasing phosphorylation at Ser-11/Ser-18 and Ser-938. Opossum kidney cells co-expressing the AT<sub>1a</sub> receptor and either alpha-1.wild-type, alpha-1.S11A/S18A or alpha-1.S938A were treated &#x00B1; 10 nM Ang II for 5 min, increasing phosphorylation at the three sites. Na,K-ATPase was bound to digoxin-affinity columns in the presence of Na, ATP, and Mg. A solution containing 30 mM NaCl and 3 mM ATP eluted ~20% of bound untreated Na,K-ATPase (Population #1). Pre-treating cells with Ang II slowed the elution of Population #1 in alpha-1.wild-type and alpha-1.S938A, but not alpha-1.S11A/S18A cells. Another 50% of bound Na,K-ATPase (Population #2) was subsequently eluted in two phases by a solution containing 150 mM NaCl and 3 mM ATP. Ang II increased the initial rate and slowed the second phase in alpha-1.wild-type, but not a-1.S938A cells. Thus, Ang II changes the conformation of two forms of EP<sub>2 </sub>via differential phosphorylation.]]></description>
	<dc:creator>K J. Massey, Q Li, N F. Rossi, R R. Mattingly, D R. Yingst</dc:creator>
	<dc:date>2011-12-07T09:52:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111398</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-07</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111220">
	<title><![CDATA[Inhibition of protein translocation at the endoplasmic reticulum promotes activation of the unfolded protein response]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111220</link>
	<description><![CDATA[<b>Selective small-molecule inhibitors represent powerful tools for the dissection of complex biological processes. Eeyarestatin I (ES<sub>I</sub>) is a novel modulator of endoplasmic reticulum (ER) function<i>. </i>Here, we show that in addition to acutely inhibiting ERAD, ES<sub>I</sub> causes production of mislocalised polypeptides that are ubiquitinated and degraded. Unexpectedly, our results suggest these nontranslocated polypeptides promote activation of the unfolded protein response (UPR), and indeed we can recapitulate UPR activation with an alternative and quite distinct inhibitor of ER translocation. These data suggest that the accumulation of nontranslocated proteins in the cytosol may represent a novel mechanism that contributes to UPR activation.</b>]]></description>
	<dc:creator>C McKibbin, A Mares, M Piacenti, H Williams, P Roboti, M Puumalainen, A C Callan, K Lesiak-Mieczkowska, S Linder, H Harant, S High, S Flitsch, R C Whitehead, E Swanton</dc:creator>
	<dc:date>2011-12-06T14:06:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111220</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-06</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111363">
	<title><![CDATA[Membrane-integration of a mitochondrial signal-anchored protein does not require additional proteinaceous factors]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111363</link>
	<description><![CDATA[The mitochondrial outer membrane (OM) contains signal-anchored proteins that bear at their N-terminus a single hydrophobic segment that serves as both a mitochondrial targeting signal and an anchor at the membrane. These proteins, like the vast majority of mitochondrial proteins, are encoded in the nucleus and have to be imported into the organelle. Currently, the mechanisms by which they are targeted to and inserted into the OM are unclear. To shed light on these issues, we employed a recombinant version of the signal-anchored protein OM45 and a synthetic peptide corresponding to its signal-anchor segment. Both forms associated with isolated mitochondria independently of cytosolic factors. Interaction with mitochondria was diminished when a mutated form of the signal-anchor was employed. We demonstrate that the signal-anchor peptide acquires an alpha-helical structure in lipid environment and adopted a transmembrane topology within artificial lipid bilayers. Moreover, the peptide&#x00B4;s affinity to artificial membranes with OM-like lipid composition was much higher than that to membranes with ER-like lipid composition. Collectively, our results suggest that signal-anchor proteins are specifically inserted into the mitochondrial OM by a process that is not dependent on additional proteins but is rather facilitated by the distinct lipid composition of this membrane.]]></description>
	<dc:creator>E Merklinger, Y Gofman, A Kedrov, A J.M. Driessen, N Ben-Tal, Y Shai, D Rapaport</dc:creator>
	<dc:date>2011-12-05T14:30:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111363</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-05</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618">
	<title><![CDATA[Lactococcus lactis HemW (HemN) is a haem-binding protein with a putative role in haem trafficking]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111618</link>
	<description><![CDATA[<i>Lactococcus lactis</i> cannot synthesize heme, but when supplied with heme, expresses a cytochrome <i>bd</i> oxidase. Aside of the <i>cydAB</i> structural genes for this oxidase, <i>L. lactis</i> features two additional genes, <i>hemH</i> and <i>hemW</i> (<i>hemN</i>), with conjectured functions in heme metabolism. While it appears clear that <i>hemH </i>encodes a ferrochelatase, no function is know for <i>hemW</i>. HemW-like proteins occur in bacteria, plants, and animals, and are usually annotated as coproporphyrinogen III dehydrogenases. However, such a function has never been demonstrated for a HemW-like protein. We here studied HemW of <i>L. lactis</i> and showed that it is devoid of coproporphyrinogen III dehydrogenase activity <i>in vivo</i> and <i>in vitro</i>. Recombinantly produced, purified HemW contained an iron-sulfur cluster and was dimeric; upon loss of the iron, the protein became monomeric. Both forms of the protein covalently bound heme <i>b</i> <i>in vitro</i>, with a stoichiometry of one heme per monomer and a K<sub>D</sub> of 8 &#x00B5;M. <i>In vivo</i>, HemW occurred as a heme free, cytosolic form, as well as a heme-containing, membrane-associated form. Addition of <i>L. lactis</i> membranes to heme-containing HemW triggered the release of heme from HemW <i>in vitro</i>. Based these findings, we propose a role of HemW in heme trafficking. HemW-like proteins form a distinct phylogenetic clade which has not previously been recognized.]]></description>
	<dc:creator>H K Abicht, J Martinez, G Layer, D Jahn, M Solioz</dc:creator>
	<dc:date>2011-12-05T14:11:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111618</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-05</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110605">
	<title><![CDATA[Structural determinants of rCNT2 sorting to the plasma membrane of polarized and non-polarized cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110605</link>
	<description><![CDATA[rCNT2 (<i>Slc28a2</i>) is the purine-preferring concentrative nucleoside transporter. It is expressed in both non polarized and polarized cells, where it is localized in the brush border membrane. Since no information about the domains implicated in the plasma membrane sorting of rCNT2 is available, this work aims at identifying structural and functional requirements for rCNT2 trafficking. 
 The comprehensive topological mapping of the intracellular N terminal tail revealed two main features: 1) a glutamate enriched region (NPGLELME) between residues 21 and 28 seems to be implicated in the stabilization of rCNT2 in the cell surface, since mutagenesis of these conserved glutamates resulted in enhanced endocytosis. 2) Mutation of a potential Casein Kinase 2 (CK2) domain led to a loss of brush border-specific sorting. Although the shortest proteins assayed (-74AA, -48AA and -37AA) were accumulated intracellularly and lost their brush border membrane preference, they were still functional. A deeper analysis of CK2 implication in CNT2 trafficking, using a CK2 specific inhibitor (DMAT) and other complementary mutations mimicking the negative charge provided by phosphorylation (S46D and S46E), demonstrated an effect of this kinase on CNT2 activity. 
 In summary, rCNT2 N-terminal tail contains dual sorting signals. An acidic region is responsible for its proper stabilization at the plasma membrane whereas the putative CK2 domain (Ser<sup>46</sup>) is implicated in the apical sorting of the transporter.]]></description>
	<dc:creator>I Pinilla-Macua, F Casado, M Pastor-Anglada</dc:creator>
	<dc:date>2011-12-02T15:33:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110605</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-02</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110247">
	<title><![CDATA[An aspartate residue in the external vestibule of GLYT2 (glycine transporter 2) controls cation access and transport coupling]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110247</link>
	<description><![CDATA[Synaptic glycine levels are controlled by glycine transporters (GLYTs). GLYT1 is the main regulator of synaptic glycine concentrations, which catalyzes Na<sup>+</sup>/Cl<sup>-</sup>/glycine cotransport with a 2:1:1 stoichiometry. By contrast, neuronal GLYT2 supplies glycine to the presynaptic terminal with a 3:1:1 stoichiometry. We subjected homology models of GLYT1 and GLYT2 to molecular dynamics simulations in the presence of Na<sup>+</sup>. Using Molecular Interaction Potential maps and <i>in silico</i> mutagenesis, we identified a conserved region in the GLYT2 external vestibule likely to be involved in Na<sup>+</sup> interactions. Replacement of D471 in this region reduced Na<sup>+</sup> affinity and Na<sup>+</sup> cooperativity of transport, an effect not produced in the homologous position (D295) in GLYT1. Unlike the GLYT1D295 mutation, this D471 mutant increased sodium leakage and non-stoichiometric uncoupled ion movements through GLYT2, as determined by simultaneously measuring current and [<sup>3</sup>H]glycine accumulation. The homologous D471 and D295 positions exhibited distinct cation-sensitive external accessibility, and they were involved in Na<sup>+</sup> and Li<sup>+</sup>-induced conformational changes. While these two cations had opposite effects on GLYT1 they had comparable effects on accessibility in GLYT2, explaining the inhibitory and stimulatory responses to lithium exhibited by the two transporters. Based on these findings, we propose a role for D471 in controlling cation access to GLYT2 Na<sup>+</sup> sites, ion coupling during transport and the subsequent conformational changes.]]></description>
	<dc:creator>G P&#x00E9;rez-Siles, E Nunez, A Morreale, E Jim&#x00E9;nez, A Leo-Mac&#x00ED;as, G Pita, F Cherubino, R Sangaletti, E Bossi, &#x00C1; R. Ort&#x00ED;z, C Aragon, B Lopez-Corcuera</dc:creator>
	<dc:date>2011-12-01T15:15:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110247</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-01</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111461">
	<title><![CDATA[Inactivation of ceramide transfer protein during pro-apoptotic stress by Golgi disassembly and caspase cleavage]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111461</link>
	<description><![CDATA[The mammalian Golgi apparatus is composed of multiple stacks of cisternal membranes organized laterally into a polarized ribbon. Furthermore, <i>trans</i>-Golgi membranes come in close apposition with endoplasmic reticulum (ER) membranes to form ER-<i>trans</i>-Golgi contact sites, which may facilitate transfer of newly synthesized ceramide from the ER to sphingomyelin (SM) synthase at the <i>trans</i>-Golgi via ceramide transfer protein (CERT). CERT interacts with both ER and Golgi membranes, and together with Golgi morphology contributes to efficient SM synthesis. Here, we show that Golgi disassembly during proapoptotic stress induced by tumor necrosis factor (TNFa) and anisomycin results in decreased levels of CERT at the Golgi region. This is accompanied by a caspase-dependent loss of full-length CERT and reduction in <i>de novo</i> SM synthesis. <i>In vitro</i>, CERT is cleaved by caspases-2, -3 and -9. Truncated versions of CERT corresponding to fragments generated by caspase-2 cleavage at Asp<sup>213</sup> were mislocalized and did not promote efficient <i>de novo</i> SM synthesis. Thus, it is likely that during cellular stress, disassembly of Golgi structure together with inactivation of CERT by caspases causes a reduction in ceramide trafficking and SM synthesis, and could contribute to the cellular response to proapoptotic stress.]]></description>
	<dc:creator>S Chandran, C E. Machamer</dc:creator>
	<dc:date>2011-12-01T11:55:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111461</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-01</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110535">
	<title><![CDATA[Inhibition of glutaminyl cyclase attenuates cell migration modulated by monocyte chemoattractant proteins]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20110535</link>
	<description><![CDATA[Glutaminyl cyclase (QC) catalyzes the formation of N-terminal pyroglutamate (pGlu) in peptides and proteins. pGlu formation in chemoattractants may participate in the regulation of macrophage activation and migration. However, a clear molecular mechanism for the regulation is lacking. This study examines the role of QC-mediated pGlu formation on monocyte chemoattractant proteins (MCPs) in inflammation. We demonstrated <i>in</i> <i>vitro</i> the pGlu formation on MCPs by QC using mass spectrometry. A potent QC inhibitor, PBD150, significantly reduced the N-terminal uncyclized MCPs precursor (preMCPs)-stimulated monocyte migration, whereas pGlu-containing MCPs (pMCPs)-induced cell migration was unaffected. QC siRNA revealed a similar inhibitory effect. Lastly, we demonstrated that inhibiting QC can attenuate cell migration by LPS. These results strongly suggest that QC-catalyzed N-terminal pGlu formation of MCPs is required for monocyte migration, and provide new insights into the role of QC in the inflammation process. Our results also suggest that QC could be a drug target for some inflammatory disorders.]]></description>
	<dc:creator>Y Chen, K Huang, W Kuo, Y Lo, Y Lee, A H.-J. Wang</dc:creator>
	<dc:date>2011-11-08T11:22:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20110535</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-11-08</prism:publicationDate>
	<prism:section>BJ ChemBio</prism:section>
</item>


</rdf:RDF>

